Supplementary Figure S4 from Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models

Authors :: Timothy R. Wilson
Mark R. Lackner
Lori S. Friedman
Ciara Metcalfe
Michael E. Goldberg
Ethan S. Sokol
Wei Zhou
Carol O'Brien
Heidi M. Savage
Heather M. Moore
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Supplementary Figure S4: Taselisib-mediated induction of ESR1 and hormone signaling is dependent on PIK3CA mutational status.

Tools